Posts

Posted on

Olema Oncology Announces Pricing of Initial Public Offering

SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Olema Oncology from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $209.0 million. All of the shares are being offered by Olema Oncology. In addition, Olema Oncology has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Global Select Market on November 19, 2020, under the ticker symbol “OLMA.” The offering is expected to close on November 23, 2020, subject to customary closing conditions.

J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC are acting as active joint book-running managers for the offering. Canaccord Genuity LLC is also acting as a book-running manager.

Registration statements relating to these securities were filed with the U.S. Securities and Exchange Commission (SEC) and became effective on November 18, 2020. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a written prospectus, forming a part of the effective registration statement. Copies of the final prospectus relating to the initial public offering can be obtained, when available, from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (212) 834-4533 or by email at [email protected]; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at +1 (833) 297-2926 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Contacts

Investor Contact:
[email protected]

Media Contact:
Sheryl Seapy, W2O
[email protected]
949-903-4750



Posted on

Harrison Co. Advises Tattooed Chef on its Business Combination with Forum Merger II Corporation

Tattooed Chef now traded on Nasdaq under the symbol “TTCF”

LOS ANGELES, Nov. 18, 2020 (GLOBE NEWSWIRE) — Harrison Co., an investment banking firm dedicated to the food, agriculture, and healthy living sectors, today announced it had advised Tattooed Chef, Inc. (“Tattooed Chef”) on its business combination with Forum Merger II Corporation (“Forum”) , a special purpose acquisition company, resulting in Tattooed Chef’s public listing on Nasdaq under the symbol “TTCF.” At the time of the closing on October 15, 2020, Tattooed Chef’s market capitalization was approximately $1.4 billion.

Tattooed Chef is a leading plant-based food company offering a broad portfolio of innovative plant-based food products that taste great and are sustainably sourced. Tattooed Chef’s signature products include ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, and cauliflower pizza crusts, which are available in the frozen food sections of leading national retail food stores across the United States as well as on Tattooed Chef’s e-commerce site. Understanding consumer lifestyle and food trends, and a commitment to innovation, allows Tattooed Chef to continuously introduce unique, delicious, and healthy products.

“Grant, Bill and the entire Harrison Co. team far exceeded our expectations. We began talking to potential investors at the beginning of shelter-in-place and despite the capital market disruptions, Grant and Bill drove our process forward and identified great alternatives. Throughout the process they were an integral part of our team, and their commitment to our company and hours of dedication were extraordinary. They are true leaders in the better-for-you category and their experience and guidance were critical to successfully closing the transaction,” said Sam Galletti, CEO of Tattooed Chef.

Grant Garbers, Partner at Harrison Co. commented, “It was an honor to represent a leading innovator in the better-for-you food industry. We believe the high quality, great taste and innovation of Tattooed Chef’s products will be attractive to an expanding universe of consumers, which should grow the market of customers seeking the company’s plant-based meals.”

“It was an honor to represent a leading innovator in the better-for-you food industry,” said Bill Harrison, Managing Partner at Harrison Co. “Tattooed Chef’s infrastructure from direct grower sourcing through in-house product development and controlled production has positioned the company to be a long-term leader in the better-for-you food sector.”

ABOUT
HARRISON CO.
Harrison Co. as an independent investment banking firm that is dedicated to advising companies in the food, agriculture, and healthy living sectors. The firm is consumer-focused and works exclusively with business owners and operators, helping its clients make and effect the right strategic business, M&A, and financing decisions to capitalize on the rapidly-changing consumer economy. The firm has nine partners and services offered include the review of strategic alternatives, merger & acquisition advisory, debt & equity private placement, fairness opinions, and financial advisory services. 

For more information visit www.harrisonco.com.

Contact

Bill Harrison
Managing Partner
+1 917 596 5533
[email protected]



Posted on

L&F Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering

L&F Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering

CHICAGO–(BUSINESS WIRE)–
L&F Acquisition Corp. (the “Company”), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses, today announced the pricing of its initial public offering of 15,000,000 units at $10.00 per unit. The units have been approved for listing on The New York Stock Exchange, or NYSE, under the symbol “LNFA.U” beginning on November 19, 2020. Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on NYSE and trade under the symbols “LNFA” and “LNFA WS,” respectively.

The Company intends to pursue a business combination with a high-growth business and concentrate its efforts on identifying technology and services businesses in the governance, risk, compliance and legal (“GRCL”) sector with an enterprise value of approximately $750 million to $2 billion. The Company is led by Chairman Jeffrey C. Hammes, Director and Chief Executive Officer Adam Gerchen, Director Richard Levy and Chief Financial Officer Tom Gazdziak.

The offering is expected to close on November 23, 2020, subject to customary closing conditions.

Jefferies LLC is serving as sole book-running manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments, if any.

The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected].

A registration statement relating to the securities became effective on November 18, 2020 in accordance with Section 8(a) of the Securities Act of 1933, as amended. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

About L&F Acquisition Corp.

L&F Acquisition Corp. is a blank check company formed for the purpose of entering into a combination with one or more businesses, with the intent to concentrate on identifying technology and services businesses in the GRCL sector. L&F Acquisition Corp. is sponsored by JAR Sponsor, LLC, a newly organized special purpose vehicle under the common control of entities affiliated with Chairman Jeffrey C. Hammes, CEO Adam Gerchen, and Victory Park Capital.

L&F Acquisition Corp.

Julia Sahin, Edelman

[email protected]

646.301.2968

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Finance Professional Services Other Technology Legal Technology

MEDIA:

Posted on

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zosano Pharma Corporation (NASDAQ: ZSAN), Celsion Corporation (NASDAQ: CLSN), Citigroup, Inc. (NYSE: C), and Raytheon Technologies Corporation (NYSE: RTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Zosano Pharma Corporation (NASDAQ: ZSAN)

Class Period: February 13, 2017 to September 30, 2020

Lead Plaintiff Deadline: December 28, 2020

Zosano is a clinical stage pharmaceutical company. Its lead product candidate is Qtrypta (M207), a formulation of zolmitriptan coated onto the Company’s microneedle patch. Its pivotal efficacy trial, called ZOTRIP, began in July 2016. In December 2019, Zosano submitted its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking regulatory approval for Qtrypta.

On September 30, 2020, Zosano disclosed receipt of a discipline review letter (“DRL”) from the FDA regarding its NDA for Qtrypta and stated that approval was not likely. According to the Company’s press release, the FDA “raised questions regarding unexpected high plasma concentrations of zolmitriptan observed in five study subjects from two pharmacokinetic studies and how the data from these subjects affect the overall clinical pharmacology section of the application.” The FDA also “raised questions regarding differences in zolmitriptan exposures observed between subjects receiving different lots of Qtrypta in the company’s clinical trials.”

On this news, the Company’s share price fell $0.92, or 57%, to close at $0.70 per share on October 1, 2020.

On October 21, 2020, Zosano disclosed receipt of a Complete Response Letter (“CRL”) from the FDA. As a result of the previously identified deficiencies, the FDA recommended that Zosano conduct a repeat bioequivalence study between three of the lots used during development.

On this news, the Company’s share price fell $0.17, or 27%, to close at $0.04440 per share on October 21, 2020.

The complaint, filed on October 29, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) that pharmocokinetic studies submitted in connection with the Company’s NDA included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) that, as a result of the foregoing differences among patient results, the FDA was reasonably likely to require further studies to support regulatory approval of Qtrypta; (4) that, as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times.

For more information on the Zosano class action go to: https://bespc.com/cases/ZSAN

Celsion Corporation (NASDAQ: CLSN)

Class Period: November 2, 2015 to July 10, 2020

Lead Plaintiff Deadline: December 28, 2020

Celsion is an integrated development clinical stage oncology drug company that focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer.

Celsion’s lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.

In February 2014, Celsion announced that the U.S. Food and Drug Administration (“FDA”) had reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radio frequency ablation (“RFA”) in primary liver cancer, also known as hepatocellular carcinoma (“HCC”), called the “OPTIMA Study.” The trial design was purportedly based on a comprehensive analysis of data from the Company’s Phase III HEAT Study, which purportedly demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival (“OS”) in a substantial number of HCC patients that received an optimized RFA treatment. 

On July 13, 2020, Celsion announced that “it ha[d] received a recommendation from the independent [DMC] to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with [RFA] for the treatment of [HCC], or primary liver cancer.” According to the Company, “[t]he recommendation was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020,” which “found that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903.”

On this news, Celsion’s stock price fell $2.29 per share, or 63.97%, to close at $1.29 per share on July 13, 2020.

The complaint, filed on October 29, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants had significantly overstated the efficacy of ThermoDox; (ii) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For more information on the Celsion class action go to: https://bespc.com/cases/CLSN

Citigroup, Inc. (NYSE: C)

Class Period: January 15, 2016 to October 12, 2020

Lead Plaintiff Deadline: December 29, 2020

The Class Period begins on February 25, 2017, following the Company’s submission of its 2016 Annual Report to the SEC. In that filing, and throughout the Class Period, Citi assured investors that there were no significant deficiencies or material weaknesses in the Company’s internal controls. When faced with periodic regulatory penalties for noncompliance, the Company continued to assure investors that the specific deficiencies at issue were being remediated promptly and that internal controls and regulatory compliance were a top priority at Citi. In particular, Citi assured investors that it satisfied all regulatory requirements and maintained adequate internal controls, data governance, compliance risk management, and enterprise risk management.

In reality, during the Class Period and unbeknownst to investors, Citi’s internal controls and risk management capabilities suffered from “serious” and “longstanding” inadequacies that exposed the Company to massive regulatory penalties and will cost significantly more than $1 billion to remediate. Specific control failures about which Citi executives were warned remained unresolved for years and the Company’s culture of non-compliance was so widespread that Citi’s CEO, Defendant Michael Corbat, exhorted employees in an internal memo that regulatory compliance required more than “checking boxes.”

The truth began to emerge on September 14, 2020, when reports surfaced that regulators were preparing to reprimand Citi for failing to improve its risk-management systems.

That disclosure caused the price of Citi’s stock to decline $2.85 per share, from $51.00 to $48.15, erasing $5.91 billion in shareholder value.

After the market closed on September 14, 2020, an internal memo sent to Citi employees revealed for the first time the Company’s disregard for adequate internal controls and regulatory compliance.

As a result, the price of Citi’s stock declined an additional $3.34 per share, from $48.15 to $44.81, erasing $6.93 billion in shareholder value.

Then, on October 13, 2020, Citi reported earnings for the third quarter of 2020, and disclosed that the Company’s expenses increased during the third quarter by 5%, to $11 billion, due to an increase in costs including a $400 million fine, investments in infrastructure, and other remediation costs related to control deficiencies.

These disclosures caused Citi’s stock price to decline by $2.20 per share, from $45.88 to $43.68, erasing $4.57 billion in shareholder value.

For more information on the Citigroup class action go to: https://bespc.com/cases/C

Raytheon Technologies Corporation (NYSE: RTX)

Class Period: February 10, 2016 to October 27, 2020

Lead Plaintiff Deadline: December 29, 2020

On October 27, 2020, after market hours, Raytheon filed its quarterly report on Form 10-Q with the SEC for the quarter ended September 30, 2020 (the “3Q20 Report”). The 3Q20 Report announced the DOJ Investigation, stating in pertinent part: “On October 8, 2020, the Company received a criminal subpoena from the DOJ seeking information and documents in connection with an investigation relating to financial accounting, internal controls over financial reporting, and cost reporting regarding Raytheon Company’s Missiles & Defense business since 2009.”

On this news, the price of Raytheon shares fell $4.19 per share, or 7%, to close at $52.34 per share on October 28, 2020, on unusually heavy trading volume, damaging investors.

The complaint, filed on October 30, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon’s Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice (“DOJ”); and (6) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

For more information on the Raytheon class action go to: https://bespc.com/cases/RTX

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected] 
www.bespc.com 



Posted on

ZOOMINFO TECHNOLOGIES ALERT: Bragar Eagel & Squire, P.C. is Investigating ZoomInfo Technologies, Inc. on Behalf of Zoom Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) —  Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ZoomInfo Technologies, Inc. (NASDAQ: ZI) on behalf of ZoomInfo stockholders. Our investigation concerns whether ZoomInfo has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On November 9, 2020, ZoomInfo announced that on November 5, 2020, the audit committee of the Company’s board of directors concluded that ZoomInfo’s Q2 2020 financial statements filed with the U.S. Securities and Exchange Commission should not be relied on. 

ZoomInfo further disclosed that it would restate those results because it improperly recorded a $21.6 million tax benefit related to the GAAP basis and tax basis of partnerships owned by corporations within ZoomInfo’s corporate structure. As a result of this improper accounting, ZoomInfo understated its Q2 2020 net loss by over 38%. 

If you purchased or otherwise acquired ZoomInfo shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com



Posted on

ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Peabody Energy Corporation Investors of Important November 27 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – BTU

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Peabody Energy Corporation (NYSE: BTU) between April 3, 2017 and October 28, 2019, inclusive (the “Class Period”), of the important November 27, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Peabody investors under the federal securities laws.

To join the Peabody class action, go to http://www.rosenlegal.com/cases-register-1962.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, from April 3, 2017 through September 28, 2018, defendants failed to disclose, and would continue to omit, the following adverse facts pertaining to the safety practices at Peabody’s North Goonyella mine, which were known to or recklessly disregarded by defendants: (1) the Company had failed to implement adequate safety controls at the North Goonyella mine to prevent the risk of a spontaneous combustion event; (2) the Company failed to follow its own safety procedures; and (3) as a result, the North Goonyella mine was at a heightened risk of shutdown. Further, according to the lawsuit, following the September 28, 2018 fire and throughout the remainder of the Class Period, defendants failed to disclose, and would continue to omit, the following adverse facts pertaining to the feasibility of Peabody’s plan to restart the North Goonyella mine: (1) the Company’s low-cost plan to restart operations at the mine posed unreasonable safety and environmental risks; (2) the Australian body responsible for ensuring acceptable health and safety standards, the Queensland Mines Inspectorate (“QMI”), would likely mandate a safer, cost-prohibitive approach; and (3) as a result, there would be major delays in reopening the North Goonyella mine and restarting coal production. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 27, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register–1962.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



Posted on

Governor Polis Proclaims Dec. 8 as Colorado Gives Day

PR Newswire

ARVADA, Colo., Nov. 18, 2020 /PRNewswire/ — Colorado Gives Day, a statewide movement to celebrate and increase philanthropy through online giving, is scheduled for 24 hours on Tuesday, December 8, 2020. Governor Polis proclaimed Dec. 8 as Colorado Gives Day, one of the nation’s largest online giving events. Colorado Gives Day encourages support and gratitude to Colorado’s nonprofits that work tirelessly year-round to sustain Colorado communities.

 

“Many nonprofits have served as first responders during COVID and it has placed a tremendous burden on their resources. Other nonprofits, like museums and theaters, have lost revenue because of the shut down and social distancing,” said Kelly Dunkin, president and CEO of Community First Foundation, the organization that runs the event. “Colorado Gives Day is our chance to support and show gratitude for the nonprofits that keep Colorado wonderful. They need us more than ever this year.”

Since its inception in 2010, Colorado Gives Day has raised $257 million for Colorado nonprofits, making it among the most successful giving days in the nation. Last year alone, donors gave more than 165,407 individual donations to 2,610 nonprofits totaling $40 million, breaking all previous records.

“As a longtime corporate partner, it’s been an honor to witness the growth in statewide giving year after year and the monumental impact it’s made on our communities,” said Brian Larson, Regional President of FirstBank. “The $40 million raised in 2019 goes a long way toward supporting Colorado nonprofits, and we’re hopeful Colorado Gives Day 2020 will have an even greater impact.”

Donors can search for local nonprofits on ColoradoGives.org to learn more and donate on Colorado Gives Day. Donations can also be scheduled now to process on Colorado Gives Day, and all donations, including scheduled donations, will be boosted by an incentive fund of more  than $1 million.  

Media notes: 

About Community First Foundation
Community First Foundation strives to connect ideas, people and resources to create lasting community solutions. Since 1975, we’ve been dedicated to listening to all voices, sharing big ideas, and co-creating innovative strategies. We help donors with philanthropic planning, support nonprofits with grants and resources, and build resilient and thriving communities through connection. More about Community First Foundation.

About FirstBank
FirstBank began providing banking services in Colorado in 1963. Today, the bank maintains more than $20 billion in assets and operates more than 110 branch locations across Colorado, Arizona and California. FirstBank offers a variety of checking accounts, savings accounts, home equity loans, mortgages, and a full range of commercial banking services, including financing, treasury management and deposit accounts. Since 2000, FirstBank has been recognized as a leader in corporate philanthropy, contributing nearly $70 million and thousands of volunteer hours to charitable organizations. The company is also unique in that a large portion of its stock is owned by management and employees, giving employees a financial stake in the bank’s success through its Employee Stock Ownership Program. For more information, visit www.efirstbank.com. Member FDIC.

Beth McConkey, 720.898.5919
[email protected]

Jake Holtrop, 713-205-0126
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/governor-polis-proclaims-dec-8-as-colorado-gives-day-301176583.html

SOURCE Community First Foundation

Posted on

Camtek Announces Pricing of Upsized Public Offering of Ordinary Shares

PR Newswire

MIGDAL HAEMEK, Israel, Nov. 18, 2020 /PRNewswire/ — Camtek Ltd. (NASDAQ: CAMT) (TASE: CAMT), a leading manufacturer of metrology and inspection equipment, announced today the pricing of an underwritten public offering of 3,500,000 ordinary shares at a price to the public of $17.00 per share. The offering was upsized from the previously announced public offering of 3,000,000 ordinary shares. In addition, Camtek has granted the underwriters a 30-day option to purchase up to an additional 525,000 ordinary shares, at the public offering price less underwriting discounts and commissions. The offering is expected to close on or about November 23, 2020, subject to customary closing conditions.

Camtek intends to use the net proceeds from the offering for general corporate purposes, including, but not limited to, potential acquisitions, working capital, capital expenditures, investments, research and development and product development. Camtek has not determined the amount of net proceeds to be used specifically for the foregoing purposes and has no agreements or understandings with respect to any acquisition or investment at this time.

Barclays and Stifel are acting as the representatives of the underwriters and as joint book-running managers for the offering and each of Needham & Company, B. Riley Securities, and Northland Capital Markets are acting as co-managers.

The securities described above are being offered by Camtek pursuant to an effective shelf registration statement on Form F-3, including a base prospectus, that was previously filed by Camtek with the Securities and Exchange Commission (the “SEC“) and that was declared effective on April 21, 2020. The offering is being made only by means of a prospectus supplement and the accompanying prospectus. Before you invest, you should read the preliminary prospectus supplement relating to the offering, which was filed with the SEC on November 18, 2020, and the accompanying prospectus included in the registration statement, which are available for free on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by email at [email protected], or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy the
securities
described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Camtek
Camtek is a leading manufacturer of metrology and inspection equipment serving the Advanced Interconnect Packaging, Memory, CMOS Image Sensors, MEMS, RF and other segments of the semiconductor industry.

Camtek provides dedicated inspection solutions and crucial yield-enhancement data, enabling manufacturers to improve yield and drive down their production costs.

With eight offices around the world, Camtek has best-in-class sales and customer support organization, providing tailor-made solutions in line with customers’ requirements.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Camtek Ltd. (“we,” “us” and “our”). Forward-looking statements can be identified by the use of words including “believe,” “anticipate,” “should,” “intend,” “plan,” “will,” “may,” “expect,” “estimate,” “project,” “positioned,” “strategy,” and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Camtek to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including as a result of the effect of the COVID-19 crisis on the global markets and on the markets in which we operate, including the risk of the continuation of disruptions to our and our customers’, providers’, business partners and contractors’ businesses as a result of the COVID-19 pandemic; our dependency upon the semiconductor industry and the risk that unfavorable economic conditions or low capital expenditures may negatively impact our operating results; the highly competitive nature of the markets we serve, some of which have dominant market participants with greater resources than us; the rapid evolvement of technology in the markets in which we operate, and our ability to adequately predict these changes or keep pace with emerging industry standards; the risks relating to the concentration of a significant portion of our business in certain countries in the Asia Pacific Region, particularly China, Taiwan and Korea; changing industry and market trends; reduced demand for our products; the timely development of our new products and their adoption by the market; increased competition in the industry; price reductions; and those other factors discussed in our Annual Report on Form 20-F and other documents filed by the Company with the SEC as well as other documents that may be subsequently filed by Camtek from time to time with the SEC.

While we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. In addition, any forward-looking statements represent Camtek’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Camtek does not assume any obligation to update any forward-looking statements unless required by law.


CAMTEK LTD.

Moshe Eisenberg, CFO

Tel: +972 4 604 8308

Mobile: +972 54 900 7100


[email protected]


INTERNATIONAL INVESTOR RELATIONS  

GK Investor Relations

Ehud Helft

Tel: (US) 1 646 688 3559


[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/camtek-announces-pricing-of-upsized-public-offering-of-ordinary-shares-301176580.html

SOURCE Camtek Ltd

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation – BSX

PR Newswire

NEW YORK, Nov. 18, 2020 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE:  BSX).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Boston Scientific and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 


[Click here for information about joining the class action]
 

On November 17, 2020, Boston Scientific announced a global recall of all unused inventory of the Company’s LOTUS Edge Aortic Valve System, citing “complexities associated with the product delivery system.”  Boston Scientific further announced that “[g]iven the additional time and investment required to develop and reintroduce an enhanced delivery system, the company has chosen to retire the entire LOTUS product platform immediately.”  

On this news, Boston Scientific’s stock price fell $3.00 per share, or 7.89%, to close at $35.03 per share on November 17, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

 

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-boston-scientific-corporation—bsx-301176570.html

SOURCE Pomerantz LLP

Posted on

VAPORESSO Donates Over 70 Million Rupiah to Indonesians Affected by the Pandemic

PR Newswire

SHENZHEN, China, Nov. 18, 2020 /PRNewswire/ — The Covid-19 pandemic has heavily impacted the communities in Indonesia, with over 440 thousand confirmed cases to date and millions of people affected by recommended stay at home measures adopted across the nation. As a response to the nationwide crisis, VAPORESSO launched the XROS charity initiative.

Together for Indonesia

Internationally renowned vaping brand, VAPORESSO, has launched a charity initiative for its Pod device XROS on the Indonesian market. Aimed to help low-income communities in the pandemic context, the company donates Rp10,000 for each XROS sold through local vaping stores. The funds are utilized to purchase food as well as basic necessity items.

VAPORESSO’s initiative received enthusiasm by both vape stores and locals in need. “The money raised from the charity proceeds will go toward buying rice and foods that we donate to people in need.” said the owner of a vaping store participating in the event.

The donation activity has reached 70 million Indonesian rupiahs to date. This significant amount has helped unemployed and low-income people and their families, as well nursing homes in Jakarta.

VAPORESSO CARE has helped over 1,200 Indonesian families so far, and the company hopes its charity activities will help many more people in the future.

Helping Communities in Need

Vaping giant SMOORE International, owner of VAPORESSO has inherited a great sense of responsibility and passion for contributing to society. Not only does it provide innovative, high-quality vaping products, but it also gives back to communities in need.

Since the start of the Covid-19 pandemic early in 2020, VAPORESSO has launched its VAPORESSO CARE project to provide local stores and communities in need with assistance.

In addition, the company has sponsored various charity auction nights and launched charity initiatives through its partners across the globe. The international events are aimed to help all communities during the pandemic and beyond.

About VAPORESSO XROS

Committed to helping communities and safeguarding the health and well-being of its customers, VAPORESSO has chosen the XROS to sponsor the VAPORESSO CARE campaign in Indonesia.

The XROS is one of the most innovative and best crafted MTL-focused pod systems. The product provides a customizable mouth-to-lung vaping experience thanks to the integrated airflow control. It complies with federal vaping regulations globally and is certified for safety by in-house and independent testing laboratories.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vaporesso-donates-over-70-million-rupiah-to-indonesians-affected-by-the-pandemic-301176578.html

SOURCE VAPORESSO